Mostrar el registro sencillo del ítem
Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
dc.contributor.author | Manso, Luis | |
dc.contributor.author | Hernando, Cristina | |
dc.contributor.author | Galán, María | |
dc.contributor.author | Oliveira, Mafalda | |
dc.contributor.author | Cabrera, Miguel A | |
dc.contributor.author | Bratos, Raquel | |
dc.contributor.author | Rodríguez, César A | |
dc.contributor.author | Ruiz-Borrego, Manuel | |
dc.contributor.author | Blanch, Salvador | |
dc.contributor.author | Llombart-Cussac, Antonio | |
dc.contributor.author | Delgado-Mingorance, Juan I | |
dc.contributor.author | Álvarez-Busto, Iñaki | |
dc.contributor.author | Gallegos, Isabel | |
dc.contributor.author | González-Cortijo, Lucía | |
dc.contributor.author | Morales, Serafín | |
dc.contributor.author | Aguirre, Elena | |
dc.contributor.author | Hernando, Blanca A | |
dc.contributor.author | Ballesteros, Ana | |
dc.contributor.author | Alés-Martínez, José E | |
dc.contributor.author | REBOREDO RENDO, CRISTINA | |
dc.contributor.author | Oltra, Amparo | |
dc.contributor.author | González-Cao, María | |
dc.contributor.author | Santisteban, Marta | |
dc.contributor.author | Malón, Diego | |
dc.contributor.author | Echeverría, Isabel | |
dc.contributor.author | García-Garre, Elisa | |
dc.contributor.author | Vega, Estela | |
dc.contributor.author | Servitja, Sònia | |
dc.contributor.author | Andrés, Raquel | |
dc.contributor.author | Robles, Carlos E | |
dc.contributor.author | López López, Rafael | |
dc.contributor.author | Galve, Elena | |
dc.contributor.author | Echarri, María J | |
dc.contributor.author | Legeren, Marta | |
dc.contributor.author | Moreno, Fernando | |
dc.date.accessioned | 2022-03-16T08:38:35Z | |
dc.date.available | 2022-03-16T08:38:35Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 0960-9776 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/33242755 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16272 | |
dc.description.abstract | BACKGROUND: This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR(+)/HER2(-)) metastatic breast cancer (mBC) patients during the compassionate use program in Spain from February 2015 to November 2017. PATIENTS AND METHODS: Patient data were collected retrospectively from 35 hospitals in Spain. Patients with HR(+)/HER2(-) mBC who had progressed on >/=4 treatments for advanced disease were eligible. RESULTS: A total of 219 patients received palbociclib in combination with aromatase inhibitors (110; 50.2%), fulvestrant (87; 39.7%), tamoxifen (8; 3.6%) or as single agent (10; 4.6%). Mean age of the patients was 58 years; 31 patients (16.1%) were premenopausal and 162 (83.9%) were postmenopausal at the beginning of treatment with palbociclib. Patients had received a median of 3 previous lines of endocrine therapy (ET) for advanced disease. Real-world tumor response (rwTR) and clinical benefit rate were 5.9% (n = 13) and 46.2% (n = 101), respectively. The median real world progression-free survival (rwPFS) was 6.0 months (95% CI 5.7-7.0) and the median overall survival was 19.0 months (95% CI 16.4-21.7). Subgroup analysis revealed a significant difference in median rwPFS in patients treated with palbociclib plus fulvestrant depending on the duration of prior treatment with fulvestrant monotherapy (>6 versus </=6 months; HR 1.93, 95% CI 1.37-2.73, p < 0.001). The most frequently reported toxicities were neutropenia, asthenia, thrombopenia and anemia. CONCLUSIONS: Palbociclib can be an effective and safe treatment option in patients with heavily pretreated endocrine-sensitive mBC, especially in those with longer PFS to previous ET. | en |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP) | en |
dc.type | Journal Article | es |
dc.authorsophos | Manso, Luis;Hernando, Cristina;Galán, María;Oliveira, Mafalda;Cabrera, Miguel A;Bratos, Raquel;Rodríguez, César A;Ruiz-Borrego, Manuel;Blanch, Salvador;Llombart-Cussac, Antonio;Delgado-Mingorance, Juan I;Álvarez-Busto, Iñaki;Gallegos, Isabel;González-Cortijo, Lucía;Morales, Serafín;Aguirre, Elena;Hernando, Blanca A;Ballesteros, Ana;Alés-Martínez, José E;Reboredo, Cristina;Oltra, Amparo;González-Cao, María;Santisteban, Marta;Malón, Diego;Echeverría, Isabel;García-Garre, Elisa;Vega, Estela;Servitja, Sònia;Andrés, Raquel;Robles, Carlos E;López, Rafael;Galve, Elena;Echarri, María J;Legeren, Marta;Moreno, Fernando | |
dc.identifier.doi | 10.1016/j.breast.2020.11.005 | |
dc.identifier.pmid | 33242755 | |
dc.identifier.sophos | 36151 | |
dc.journal.title | BREAST | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Oncoloxía médica | es |
dc.relation.publisherversion | https://www.thebreastonline.com/article/S0960-9776(20)30211-3/pdf | es |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | CHUAC | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 54. | es |